Ackman, Icahn Discuss Reconciling Differences at Delivering Alpha

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Ackman, Icahn Discuss Reconciling Differences at Delivering Alpha

Aegis Comments on FDA 510(k) Approval of Bausch + Lomb's VICTUS (VRX)

July 17, 2014 9:56 AM EDT

Aegis Capital affirms Valeant Pharmaceuticals (NYSE: VRX) at Buy with a price target of $180 following news earlier that the company's wholly-owned subsidiary, Bausch + Lomb, has received 510(k) clearance from the FDA for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery.

Analyst Ram Selvaraju commented, In our view, this approval demonstrates the growth potential of the Bausch + Lomb product portfolio and also showcases Valeant's continued commitment to launching new products in high-growth,... More